By Pietro Lombardi

Novartis AG's Sandoz division is evaluating its options, including a potential appeal to the U.S. Supreme Court, after a U.S. court ruled against the company in a patent litigation related to the Sandoz biosimilar Erelzi.

The Swiss drugmaker said Wednesday that the U.S. Court of Appeals for the Federal District upheld a previous ruling declaring Amgen Inc.'s patents valid.

"Sandoz will continue its efforts to make Erelzi available to U.S. patients with autoimmune and inflammatory diseases," said Carol Lynch, president of Sandoz U.S. and head of North America. "Our company respects valid intellectual property, however Sandoz continues to believe the patents asserted by Amgen are not valid, and that it should not be able to use them to extend the drug's exclusivity."

Sandoz's biosimilar Erelzi was approved by the U.S. Food and Drug Administration in 2016 but the company hasn't been able to launch it in the U.S. due to the patent litigation with Amgen.

Write to Pietro Lombardi at pietro.lombardi@dowjones.com

(END) Dow Jones Newswires

July 01, 2020 12:45 ET (16:45 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Grafico Azioni Novartis (NYSE:NVS)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Novartis
Grafico Azioni Novartis (NYSE:NVS)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Novartis